FDA accepts Synergy’s sNDA for Trulance to treat adults with IBS-C
The Prescription Drug User Fee Act (PDUFA) date is January 24, 2018. TRULANCE is a once-daily tablet approved by the FDA for the treatment of adults with chronic
Germany-based Merck KGaA (Merck) has completed its previously announced acquisition of the chromatography business of JSR Life Sciences.
The project will use AbCellera’s single-cell screening platform to profile vaccine-specific human antibodies elicited by seasonal influenza vaccination and to generate large panels of human monoclonal antibodies with
The study dubbed APHINITY, compared Perjeta-based regimen with Herceptin and chemotherapy alone as an adjuvant therapy in 4,805 people with operable HER2-positive eBC. The Perjeta-based regimen is made up of
The new cognitive solution will use real-world data and advanced analytical techniques to better understand the anticipated outcomes of several breast cancer treatments. Novartis expertise in breast cancer, along with IBM